-
Obstructive sleep apnea (OSA) is inextricably linked with adverse cardiovascular events including stroke, MI, hypertension (HTN), and arrhythmia.
-
The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
-
The FDA has approved the first oral, selective vasopressin V2-receptor antagonist for the treatment of hypervolemic and euvolemic hyponatremia.
-
A polypill consisting of low doses of thiazide, atenolol, ramipril, simvastatin, and aspirin administered to 2053 subjects in 50 centers in India was effective in reducing multiple risk factors and cardiovascular risk.
-
A review of large randomized clinical trials for type 2 diabetes controlling HbA1c as low as 6.5-7.0% showed many consequences, but uncertain benefits. A new approach to type 2 diabetes should include individualized HbA1c targets along with cardiovascular risk reduction reflecting patients' values and preferences, and caution is urged in using these HbA1c values as performance measures to indicate inadequate care.
-
A higher intensity of comprehensive disease management for smoking cessation, similar to other chronic diseases, may yield superior results.
-
Clopidogrel and proton pump inhibitors; adverse events with tamsulosin after cataract surgery; new guidelines for persistent pain in the elderly; and FDA Actions.
-
The ECG above was obtained from a 61-year-old woman. There are a number of abnormal findings on this tracing. How many can you identify? Depending on the clinical history, which of these findings might be cause for immediate concern?
-
Aspirin reduces the risk for myocardial infarction in men ages 45-79 and for stroke in women ages 55-79; however, its use must be balanced against the increased risk of serious bleeding events in each individual patient.
-
When using an NSAID, a physician must weigh the anticipated therapeutic benefits and assess the potential risks from both the cardiovascular and gastrointestinal perspectives, and the final therapeutic decision should be individualized.
